About DNAnexus
DNAnexus is a Healthcare company based in Mountain View (United States) founded in 2009. Cloud-based genome informatics and data management are provided. DNAnexus has raised $472.55 million across 11 funding rounds from investors including Regeneron Pharmaceuticals, Blackstone and TPG. DNAnexus was last valued at $600 million in March 2022. Its chief executive, as recorded, is Richard Daly. Its website dnanexus.com draws about 170 thousand monthly visits. DNAnexus offers products and services including DNAnexus Platform, Bioinformatics Tools, and Collaboration Services. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is DNAnexus, Inc. Its competitors include Cytel, Seven Bridges Genomics and Metagenomi; 3 of its 3 listed competitors have raised funding.
Company details
DNAnexus was founded in 2009 and is headquartered in Mountain View, United States. Tools for cloud-based genome informatics and data management are offered to enterprises involved in genomic medicine. Raw sequencing data is analyzed through the platform, while genomic information is integrated with clinical and phenotypic data. Seamless collaboration among organizations is facilitated in this sector.
- Headquarters Mountain View, United States
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website dnanexus.com
- Social LinkedIn X Facebook YouTube
- Legal Name Dnanexus, Inc.
- Total Equity Funding$472.55M (USD)
in 11 rounds
- Latest Funding Round$200M (USD), Series H
Mar 2022
- InvestorsRegeneron Pharmaceuticals
& 17 more
Products & Services of DNAnexus
DNAnexus offers a comprehensive portfolio of products and services, including DNAnexus Platform, Bioinformatics Tools, and Collaboration Services.
Cloud-based tool for organizing and analyzing omics datasets securely.
Suite of apps for processing and visualizing genomic data efficiently.
Environment for team-based data sharing and compliance management.
Apps and channels of DNAnexus
its YouTube channel DNAnexus has 2.06K subscribers and 30 videos.
Videos from DNAnexus
The most watched videos on DNAnexus's YouTube channel, DNAnexus (2.06K subscribers). Click a video to play it here.
More on DNAnexus.
Funding Insights of DNAnexus
DNAnexus has successfully raised a total of $472.55M across 11 strategic funding rounds. The most recent funding activity was a Series H round of $200 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $472.55M
- Total Rounds 11
- Last Round Series H — $200M
- First Round $1.55M
(Jul 2009)
- Investors Count 18
Latest 10 of 11 funding rounds of DNAnexus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $200M | Series H | $600M | Blackstone | |
| Jun 2020 | $100M | Series G | – | Perceptive Advisors, Northpond Ventures | |
| Feb 2019 | Debt – Conventional | – | – | ||
| Feb 2019 | $68M | Series F | – | Google Ventures, Foresite Capital | – |
| Jan 2018 | $58M | Series E | – | Foresite Capital | |
| Apr 2015 | $15M | Series D | – | WuXi PharmaTech | – |
| Jan 2014 | $15M | Series C | – | TPG, First Round Capital | – |
| Oct 2011 | $15M | Series B | – | Google Ventures, TPG | |
| Sep 2010 | $74,477 | Grant | – | – | |
| Sep 2010 | $74,477 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2022 | $600M | •••••••• |
Last known valuation $600M (Mar 2022). 18 investors in total: 18 institutional.
Investors in DNAnexus
DNAnexus has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, Blackstone and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Diversified debt funding is provided for growth capital opportunities. | innovatuscp.com | New York, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
US focused seed and early-stage VC firm | firstround.com | San Francisco, United States | ||
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries. | claremontcreek.com | |||
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States |
Investor details for DNAnexus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DNAnexus
142 people are tracked at DNAnexus (44 in leadership, 6 in board & advisors, 92 in team).
| Name | Role | Group |
|---|---|---|
Richard Daly | CEO | Leadership |
Joshua Greenberg | Director Of IT | Leadership |
Walter Albro | Program Director, Success Group | Leadership |
Kelsey Steller | Brand Director | Leadership |
Kelly Green | Chief People Officer | Leadership |
James Mcnicholas | Chief Financial Officer | Leadership |
Margarita Kitova, MBA | Director Of Demand Generation | Leadership |
Ketan Doshi | Senior Vice President Of Engineering | Leadership |
Kaveh Nafissi | Director, Platform Operations | Leadership |
Esther Lee | Sr. Director, Sales Operations, Business Planning & Revenue At Dnanexus | Leadership |
Davis Feng | Customer Success Director | Leadership |
Florence Juge-Boulogne, PMP | Chief Of Staff, CTO Office | Leadership |
Juraj Kojdjak | Director Of Engineering | Leadership |
Katherine Wendelsdorf | Head Of Product, Partner Solutions | Leadership |
Anand Rao | Head Of Industry Marketing – Pharma | Leadership |
Fabian Grandke | Solutions Science Director | Leadership |
Thomas Laur | Chief Executive Officer | Leadership |
Keegan Kelsey | Director, Engineering | Leadership |
George Asimenos | CTO | Leadership |
Cara Rollag | Sr. Director, People Operations | Leadership |
122 more people are available in the full profile.
Complete people profiles for DNAnexus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DNAnexus
4 dated milestones of DNAnexus across 13 years, from founding to its latest funding, stage changes and deals.
- Founded DNAnexus is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series H, of $200.0M.
- Milestone Reaches Minicorn status.
Competitors of DNAnexus
DNAnexus has 3 listed competitors in our database, 3 of them funded. They include Cytel, Seven Bridges Genomics and Metagenomi.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| metagenomi.co | 2016 | Berkeley, United States | $376.37M | Next-generation gene editing tools are developed for drug enhancement. |
Detailed competitors of DNAnexus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DNAnexus
The website of DNAnexus (dnanexus.com) receives about 169.9K visits a month.
- Monthly visits169.9K
▲ 11.8% vs previous month
Websites whose visitors overlap most with DNAnexus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| illumina.com | 100% | 672.7K | #61,793 | View details | |
| welgene.com.tw | 86% | 2K | #7,899,866 | View details | |
genomics.xprize.org | genomics.xprize.org | 83% | – | ||
| genome.gov | 83% | 896.6K | #82,554 | View details | |
| ebi.ac.uk | 83% | 1.2M | #38,263 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for DNAnexus
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as DNAnexus (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dnanexus
Complete news archive for DNAnexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DNAnexus
DNAnexus was founded in 2009.
DNAnexus is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Richard Daly is the CEO of DNAnexus, as recorded in our data.
DNAnexus is a funded company, having raised a total of $472.55M across 11 funding rounds to date. The company's 1st funding round was a Grant of $74.48K, raised on Jul 2009.
DNAnexus was founded in 2009 and is headquartered in Mountain View, United States. Tools for cloud-based genome informatics and data management are offered to enterprises involved in genomic medicine. Raw sequencing data is analyzed through the platform, while genomic information is integrated with clinical and phenotypic data. Seamless collaboration among organizations is facilitated in this sector.
DNAnexus's top competitors include Cytel, Metagenomi and Seven Bridges Genomics.
DNAnexus offers DNAnexus Platform, Bioinformatics Tools, and Collaboration Services.
DNAnexus has 18 investors. Key investors include Regeneron Pharmaceuticals, Blackstone, TPG, HHS, and MidCap Financial.
The valuation of DNAnexus is $600M as of Mar 2022.
DNAnexus operates through Dnanexus, Inc..
The website of DNAnexus receives about 170 thousand visits a month.